Perspectivas no tratamento da doença de Alzheimer
uma revisão sobre substâncias farmacológicas promissoras
Palavras-chave:
Doença de Alzheimer, Mecanismos moleculares de ação farmacológica, Quimioterapia, Peptídeos beta-amiloides, TauopatiasResumo
CONTEXTO E OBJETIVO: A demência é uma síndrome caracterizada por declínio funcional e cognitivo, sendo a doença de Alzheimer (DA) uma das causas mais comuns e de alta prevalência em idosos. Sabe-se que não há medicamento capaz de interferir no curso da doença e as pesquisas para o tratamento da DA têm sido marcadas pelo surgimento e abandono de novas drogas. O objetivo deste estudo foi descrever as drogas capazes de influenciar o curso da DA que têm sido estudadas para o tratamento da doença. TIPO DE ESTUDO E LOCAL: Revisão narrativa de artigos originais publicados mundialmente. MÉTODOS: Foi realizada uma busca sistematizada nas bases de dados PubMed/MEDLINE, Cochrane Library/Cochrane e SciELO/Bireme. Cada um dos seguintes descritores “Mecanismos Moleculares de Ação Farmacológica” e “Quimioterapia” foram combinados com o descritor “Doença de Alzheimer”, todos encontrados no MeSH e DeCS. Os descritores foram usados sozinhos ou em combinação, fixando como filtros as publicações de 2009 a 2015, em língua inglesa, espanhola e portuguesa. RESULTADOS: Foram encontrados 6.888 artigos, dos quais 37 foram incluídos nesta revisão; 70,3% dos artigos selecionados tiveram boa qualidade com baixo ou indefinido risco de viés. Foram elencadas 86 drogas promissoras ao tratamento da AD. Elas foram classificadas em 20 categorias farmacológicas. CONCLUSÃO: Não há fármacos capazes de interferir no curso da DA com efetividade e segurança no tratamento. Contudo, os imunomoduladores foram considerados promissores devido ao fato de apresentarem efetividade e qualidade nos artigos analisados
Downloads
Referências
Chaves MLF, Godinho CC, Porto CS, et al. Doença de Alzheimer: avaliação cognitiva, comportamental e funcional. Dement Neuropsychol. 2011;5(supl 1):21-33.
World Health Organization. Neurological disorders: public health challenges. Switzerland: World Health Organization Library Cataloguing-in-Publication Data; 2006. Available from: http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf. Accessed in 2016 (Jan 8).
American Psychiatric Association. Delirium, dementia, and amnestic and other cognitive disorders. In: American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. American Psychiatric Association; 1994. p. 123-64. Available from: https://justines2010blog.files.wordpress.com/2011/03/dsm-iv.pdf. Accessed in 2016 (Jan 8).
Larson EB, Kukull WA, Katzman RL. Cognitive impairment: dementia and Alzheimer’s disease. Annu Rev Public Health. 1992;13:431-49.
van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005;76 Suppl 5:v2-7.
Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimer’s disease. Neurology. 2005;64(12 Suppl 3):S34-9.
Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140(7):501-9.
Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-81.
Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. Lancet. 1997;349(9064):1546-9.
Slattum PW, Peron EP, Hill AM. Alzheimer’s disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach. 7th ed. United States: McGraw-Hill; 2008. p. 1051-68.
Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer’s- related amyloid beta oligomers. J Neurosci. 2004;24(45):10191-200.
Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774.
Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996;16(4):881-91.
Dekosky ST, Lopez OL. Alzheimer’s disease. In: Growdon JH, Rossor MN. The Dementias 2. China: Butterworth Heinemann; 2007. p. 33-58.
Tanović A, Alfaro V. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer’s disease and vascular dementia]. Rev Neurol. 2006;42(10):607-16.
Cavalcanti JLS, Engelhardt E. Aspectos da fisiopatologia da doença de Alzheimer esporádica [Pathophysiological features of sporadic Alzheimer’s disease]. Rev Bras Neurol. 2012;48(4):21-9.
Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of
care for patients with dementia resulting from Alzheimer’s disease. Am J Geriatr Psychiatry. 2006;14(7):561-72.
León R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev. 2013;33(1):139-89.
Konrath EL, Passos Cdos S, Klein LC Jr, Henriques AT. Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer’s disease. J Pharm Pharmacol. 2013;65(12):1701-25.
McGuinness B, O’Hare J, Craig D, et al. Cochrane review on ‘Statins for the treatment of dementia’. Int J Geriatr Psychiatry. 2013;28(2):119-26.
Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal. 2012;2012:756357.
Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35(1-2):1-22.
Vale FAC, Corrêa Neto Y, Bertolucci PHF, et al. Tratamento da doença de Alzheimer. Dement Neuropsychol. 2011;5(supl 1):34-48.
Higgins JP, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions: Cochrane book series. Chichester: John Wiley & Sons; 2008. p. 481-529.
Pettenati C, Annicchiarico R, Caltagirone C. Clinical pharmacology of anti-Alzheimer drugs. Fundam Clin Pharmacol. 2003;17(6):659-72.
Sun X, Jin L, Ling P. Review of drugs for Alzheimer’s disease. Drug Discov Ther. 2012;6(6):285-90.
Yoo KY, Park SY. Terpenoids as potential anti-Alzheimer’s disease therapeutics. Molecules. 2012;17(3):3524-38.
Dodel R. [Towards a vaccine against Alzheimer’s?]. Drug Res (Stuttg). 2013;63 Suppl 1:S18-20.
Mikulca JA, Nguyen V, Gajdosik DA, et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther. 2014;39(1):25-37.
Shukla V, Skuntz S, Pant HC. Deregulated Cdk5 activity is involved in inducing Alzheimer’s disease. Arch Med Res. 2012;43(8):655-62.
Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311-21.
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322-33.
Enciu AM, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2013;2013:316495.
Feng Y, Wang X. Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:472932.
Wolfe MS. γ-Secretase inhibitors and modulators for Alzheimer’s disease. J Neurochem. 2012;120 Suppl 1:89-98.
Ghosh AK, Brindisi M, Tang J. Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012;120 Suppl 1:71-83.
Hopkins CR. ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic. ACS Chem Neurosci. 2011;2(6):279-80.
Piccinni A, Origlia N, Veltri A, et al. Neurodegeneration, β-amyloid and mood disorders: state of the art and future perspectives. Int J Geriatr Psychiatry. 2013;28(7):661-71.
Echeverria V, Zeitlin R. Cotinine: a potential new therapeutic agent against Alzheimer’s disease. CNS Neurosci Ther. 2012;18(7):517-23.
Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27(7):505-14.
Morris JK, Burns JM. Insulin: an emerging treatment for Alzheimer’s disease dementia? Curr Neurol Neurosci Rep. 2012;12(5):520-7.
Xu S, Liu G, Bao X, et al. Rosiglitazone prevents amyloid-β oligomer- induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number. J Alzheimers Dis. 2014;39(2):239-51.
Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer’s disease with combined amyloid-β and cerebrovascular pathology. PloS One. 2013;8(7):e68612.
Fukasawa H, Nakagomi M, Yamagata N, et al. Tamibarotene: a candidate retinoid drug for Alzheimer’s disease. Biol Pharm Bull. 2012;35(8):1206-12.
Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-58.
Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ. Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease. Future Med Chem. 2012;4(13):1751-61.
García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem Neurosci. 2012;3(11):832-44.
Evans DA, Morris MC, Rajan KB. Vitamin E, memantine, and Alzheimer disease. JAMA. 2014;311(1):29-30.
Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci. 2013;38(1):6-23.
Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy. 2011;31(5):490-502.
Freund Levi Y, Vedin I, Cederholm T, et al. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study. J Intern Med. 2014;275(4):428-36.
Sun GY, He Y, Chuang DY, et al. Integrating cytosolic phospholipase A2 with oxidative/nitrosative signaling pathways in neurons: a novel therapeutic strategy for AD. Mol Neurobiol. 2012;46(1):85-95.
Koliaki CC, Messini C, Tsolaki M. Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study. CNS Neurosci Ther. 2012;18(4):302-12.
Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women’s Health Initiative 10 years on. Climacteric. 2012;15(3):256-62.
Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: the case for isradipine. Biochim Biophys Acta. 2011;1812(12):1584-90.
Valenzuela M, Esler M, Ritchie K, Brodaty H. Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention. Transl Psychiatry. 2012;2:e107.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
